Available online www.jsaer.com

***Journal of Scientific and Engineering Research*, 2021, 8(5):154-159**

Research Article

ISSN: 2394-2630
CODEN(USA): JSERBR

Unraveling the Enigma: Understanding Hepatitis C and Its treatment options

Bhavinkumar B Shah

Abstract Hepatitis C virus (HCV) infection continues to be a significant health problem worldwide, impacting millions of people. This article thoroughly examines HCV, emphasizing its epidemiology, transmission, clinical signs, diagnosis, therapy, and prevention efforts.

According to epidemiological statistics, various demographics and areas have variable rates of HCV infection. The significance of prevention activities is emphasized as several transmission routes are covered, such as vertical transmission, healthcare-associated transmission, and bloodborne transmission.

Hepatitis C can cause asymptomatic infection or major liver diseases such as cirrhosis and hepatocellular cancer. Serological and molecular approaches are essential for HCV detection and surveillance. Advances in treatment options, particularly Direct-acting antivirals (DAA), have transformed Hepatitis C treatment, giving high cure rates and better tolerability than interferonbased regimens. Access to treatment and medication resistance highlights the need for continuing research and healthcare infrastructure improvement.

This article explores the complexities of the condition, including its causes, impacts, treatments, and broader ramifications. It intends to shed light on this health issue, which needs to be understood and appreciated.

Keywords Hepatitis C, global elimination, direct-acting antiviral drugs, Cirrhosis

Introduction

Hepatitis C is a viral infection that results in liver inflammation, potentially resulting in severe liver damage. The hepatitis C virus (HCV) is responsible for the infection.

Hepatitis C virus (HCV) infection is a significant worldwide health issue. Long-term infection can result in liver cirrhosis, hepatic decompensation, and hepatocellular cancer, which are linked to substantial illness and death rates. [1] In the United States, more than 4 million individuals have encountered hepatitis C, while worldwide, the number of people exposed exceeds 170 million. [2] Transmission of the hepatitis C virus occurs through direct contact with the blood of an infected individual. These days, needle sharing is the most common way for people to contract the hepatitis C virus, which causes liver infection. Although some people recover quickly from hepatitis C, the virus causes chronic liver disease in over 50% of those who have it. Conditions such as cirrhosis and liver cancer, which can be fatal, are possible outcomes of chronic hepatitis C. People who have chronic hepatitis C may not feel ill or show any symptoms at all. When symptoms manifest, it usually means that liver disease has progressed to a severe stage. [3] [4] [5]



Symptoms

There is an acute phase to every chronic hepatitis C infection. Due to the low symptom burden, acute hepatitis C is often misdiagnosed. During this stage, symptoms may manifest as jaundice, lethargy, nausea, fever, and muscular pains.

The phrase "chronic hepatitis C" describes a virus infection that lasts for an extended period. In most cases, chronic hepatitis C goes unnoticed for a long time. The virus must inflict sufficient damage to the liver before any symptoms manifest.

Some possible symptoms are:

- Easy to bleed
- Easy to bruise
- Too tired.
- Not eager to eat
- Jaundice is the name for skin that turns yellow. This could be more common in white people. In white, black, and brown people, the whites of their eyes turn yellow
- Dark urine
- Itchy skin.
- Ascites is the name for fluid buildup in the stomach area.
- Legs getting swollen.
- Losing weight
- Headaches, confusion, and slurred speech are all signs of liver encephalopathy. ˙ Spider angiomas are skin growths that look like spider webs.

Not all cases of acute hepatitis C progress to chronic infection. Some individuals can rid their bodies of the virus following the acute phase. "Spontaneous viral clearance" describes this phenomenon. Clearing acute hepatitis C is another benefit of antiviral treatment. [7]

Testing [8]

- People with HIV
- People who ever injected drugs and shared needles, syringes, or other drug preparation equipment, including those who injected once or a few times many years ago.
- People with selected medical conditions, including
- people who ever received maintenance hemodialysis
- people with persistently abnormal ALT levels
- Prior recipients of transfusions or organ transplants, including:
- People who received clotting factor concentrates produced before 1987
- people who received a transfusion of blood or blood components before July 1992 • people who received an organ transplant before July 1992
- people who were notified that they received blood from a donor who later tested positive for HCV infection.
- Healthcare, emergency medical, and public safety personnel after needle sticks, sharps, or mucosal exposures to HCV-positive blood
- Children born to mothers with HCV infection.

Routine periodic testing for people with ongoing risk factors while risk factors persist:

- People who currently inject drugs and share needles, syringes, or other drug-preparation equipment.
- People with selected medical conditions, including: • People who have received maintenance hemodialysis.

Distribution of Genotype

Even though HCV genotypes 1 and 3 are more widespread than any other genotype globally, many HCV cases are still attributable to genotypes more prevalent in low-income countries. Genotype 2 is predominant in West Africa and certain regions of South America [9], whereas genotypes 4 and 6 are typical in East and Southeast Asia and Central and North Africa, respectively. According to our estimation, the combined prevalence of genotypes 2, 4, and 6 constitutes approximately 25% of all HCV cases worldwide.

Treatment

Direct-acting antivirals (DAAs) are the predominant drugs used to treat hepatitis C. A standard treatment regimen often involves the administration of a mixture of two or more Direct-Acting Antivirals (DAAs). Occasionally, physicians may also integrate direct-acting antivirals (DAAs) with ribavirin or interferons.

Interferon antiviral treatment

a) IFN-α monotherapy: Interferon-alfa (IFN-α) monotherapy has been used to treat individuals with chronic hepatitis C (CHC) since 1986. There are two distinct but complementary mechanisms for the antiviral effects of IFN-*α*: (a) induction of a non-virus-specific antiviral state in infected cells, resulting in direct inhibition of viral replication, and (b) immunomodulatory effects that enhance the host's specific antiviral immune responses and may accelerate the death of infected cells Nevertheless, the percentage of sustained response is just around 8% to 9%. The percentage of sustained virological responses (SVRs) is around 30% in patients with hepatitis C virus genotype 1 (HCV-1), whereas it is over 65% in individuals with HCV-2 or HCV-3. Interferon-alfa (IFN-α) monotherapy has been seen to normalize alanine aminotransferase (ALT) levels in a small number of individuals diagnosed with non-A, non-B hepatitis, even before the identification of hepatitis C virus (HCV) as the primary cause of this condition [1]. The first instances of effective treatment of established chronic hepatitis C (CHC) with IFN-α monotherapy were described in 1989. However, it was usual for patients to have a recurrence after stopping the medication. [10]

b) Peginterferon (PegIFN): PegIFN results from pegylation, which involves attaching inactive polyethylene glycol (PEG) polymers to a therapeutic protein like IFN. The compound's increased molecular size leads to a longer half-life due to decreased clearance while maintaining its biological

action, enabling a more convenient dosage once a week. The study examined two PegIFNs, namely PegIFN-α-2a and PegIFN-α-2b. PegIFN-α-2a is a branching molecule weighing 40 kDa and has a terminal half-life of 80 hours. On the other hand, PegIFN-α-2b is a linear molecule weighing 12 kDa and has an average terminal half-life of 40 hours. [10]

Ribavarin

RBV is an artificial compound that belongs to the triazole guanosine family. It can combat viruses that affect both DNA and RNA. The mechanisms of action for RBV include the regulation of T helper-1 and -2 lymphocyte imbalance, reduction of cell guanosine triphosphate levels by inhibiting inosine monophosphate dehydrogenase, inhibition of the viral RNA-dependent RNA polymerase, disruption of translation by preventing the capping of messenger viral RNA, and induction of lethal viral mutagenesis. The combination of RBV and PEG-IFNα was more effective than using PEG-IFNα alone, resulting in an approximately 30% increase in sustained virologic response (SVR) rate among patients who received the RBV regimen. PEG-IFNα and RBV together also decreased the likelihood of viral recurrence after therapy. [11]

Direct-acting antivirals (DAA)

A dramatic improvement in HCV therapy occurred in 2011 with the introduction of new drugs called direct-acting antivirals (DAA), which produced a virological response more significant than 90% in most genotypes. DAAs may be classified into three primary categories based on their specific target action locations. The first category consists of NS3/4A inhibitors, which include boceprevir, telaprevir, simeprevir, asunaprevir, grazoprevir, and paritaprevir - all of which are enhanced by ritonavir. The second category consists of NS5A inhibitors, which include daclatasvir (DCV), ledipasvir, ombitasvir, elbasvir, and velpatasvir. The third type consists of NS5B nucleotide inhibitors, such as sofosbuvir, and non-nucleoside polymerase inhibitors, such as dasabuvir. [12] [13]



Figure 1: Proteins encoded by the hepatitis C virus genome as targets for direct-acting antiviral agents. *[14]*

Timeline for DAA approval [14]

Date of Drug approval

On May 13th, Boceprevir was approved by the FDA for the treatment of chronic HCV to be 2011 used, in combination with peginterferon alfa and ribavirin, in adult patients.

Approval	Drug
On May 23th, 2011	Telaprevir was approved by the FDA to be used in combination with peginterferon alfa and ribavirin for the treatment of HCV infection in adults.
In November, 2013	Simeprevir was approved by the FDA to be used in combination with peginterferon alfa and ribavirin or in combination with sofosbuvir.
In December, 2013	Sofosbuvir was approved to be used in combination with ribavirin or with pegylated interferon and ribavirin.
In October, 2014	(Ledipasvir/Sofosbuvir) were approved by the FDA in one tablet.
In December, 2014	FDA approved a combination (ombitasvir/paritaprevir/ritonavir and dasabuvir) for the treatment of patients with genotype 1.
In July, 2015	Daclatasvir was approved to be used with sofosbuvir.
	A combination (ombitasvir, paritaprevir and ritonavir) in one tablet to be used in combination with ribavirin for the treatment of HCV genotype 4 infections.
In January, 2016	On January 28th FDA approved a combination of elbasvir and grazoprevir, with or without ribavirin for treating patients with genotype 4.
In July, 2016	A combination of sofosbuvir plus velpatasvir were approved with or without ribavirin for treating adult patients in all genotypes.

Conclusion

Modern hepatitis C treatments have come a long way, allowing for excellent disease management and high cure rates. Since their introduction, direct-acting antivirals (DAAs) have transformed the treatment and management of hepatitis C.

Direct-acting antivirals for Hepatitis C virus (HCV) inhibit viral replication by focusing on specific stages of the HCV lifecycle. Many patients report a cure rate of 90% or more with these medications. Compared to pegylated interferon and ribavirin, two older treatments with lower cure rates and more difficulty to take, they also have fewer adverse effects.

Numerous patient-specific criteria influence the selection of a DAA regimen, including the HCV genotype, liver damage (cirrhosis), and prior treatment history. Several DAA drugs are frequently used, including sofosbuvir, ledipasvir, daclatasvir, and velpatasvir. For most patients, the recommended course of treatment consists of taking a single tablet of each medicine once daily for eight to twelve weeks.

Although DAAs effectively cure the illness, they cannot stop its recurrence. Hence, it is important to advise patients vulnerable to reinfection on measures they may take to lessen their risk.

The ultimate objective of treating hepatitis C is establishing a sustained virologic response (SVR), defined as the patient's blood not containing any detectable HCV RNA twelve weeks after medication. Reaching an SVR is equivalent to curing the virus.

To ensure the greatest potential result depending on the individual's unique circumstances, it is always advisable to consult a healthcare professional who specializes in liver illnesses, such as a hepatologist or an infectious disease expert, before making any treatment choices.

The development of direct-acting antivirals (DAAs) has, all things considered, greatly improved prognoses for hepatitis C patients, rendering curable in the vast majority of instances a condition that was before chronic and often progressive.

References

[1]. L. Sandmann, B. Schulte, M. P. Manns and B. Maasoumy, "Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications," *visceral medicine*, vol. 35, no. 3, pp. 161-170, 2019.

[2]. K.-M. D. N. O. M. G. G. F. M. L. K. R. M. H. Alter MJ, "The prevalence of hepatitis C virus infection in the United States, 1988 through 1994," *pubmed*, vol. 341, no. 8, pp. 55662, 1999.

[3]. "cdc," 4 2021. [Online]. Available: https://www.cdc.gov/hepatitis/hcv/index.. [Accessed 2 7 2021].

[4]. A. MJ, "Epidemiology of hepatitis C virus infection.," *pubmed*, vol. 13, no. 7, pp. 243641, 2007.

[5]. B. B. K. W. A. M. Williams IT, "Incidence and transmission patterns of acute hepatitis C in the United States,," *pubmed*, vol. 171, no. 3, pp. 242-8, 2011.

[6]. "mayoclinic," 7 2020. [Online]. [Accessed 3 8 2021].

[7]. medscape, 2020. [Online]. [Accessed 2 8 2021].
[8]. "U.S department of health and human services," [Online]. Available: https://www.hhs.gov/hepatitis/. [Accessed 03 08 2021].
[9]. P. V. e. a. Markov, ""Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam."," *Journal of virology*, vol. 86, no. 14, pp. 7677-7687, 2012.
[10]. H. &. Y. L. Chen, "Evolution of Interferon-Based Therapy for Chronic Hepatitis C," *Hepatitis Research and Treatment*, 2010.
[11]. P. K. S. &. W. E. Mathur, "Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era.," *Journal of Clinical and Translational Hepatology*, vol. 6, no. 4, pp. 431-437, 2018.
[12]. T. a. P. M. Asselah, ""Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow."," *Liver International*, vol. 32, pp. 88-102, 2012.
[13]. D. A. a. K. R. R. Herbst, ""NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection."," *Expert opinion on investigational drugs*, vol. 22, no. 10, pp. 1337-1346, 2013.
[14]. A. I. Y. F. E. N. M. &. I. M. A. Geddawy, "Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.," *Journal of Translational Internal Medicine*, vol. 5, no. 1, pp. 8-17, 2017.
[15]. B. B. K. W. A. M. Williams IT, "Incidence and transmission patterns of acute hepatitis C in the United States," *pubmed*, vol. 171, no. 3, pp. 242-8, 2011.